Selective HASPIN inhibitors

Patent number:

WO2022200433

Comunidad de Madrid.svg
No items found.

The CNIO has developed a novel group of compounds with a tricyclic core based on imidazo[1,2-b]pyridazine, which are inhibitors of the protein kinase HASPIN. The present invention relates to a group of compounds with a tricyclic core based on imidazo[1,2-b]pyridazine which are inhibitors of HASPIN, whose activity is required for the proliferation of certain tumoral cells, so the compounds of the invention are useful for the prevention and/or treatment of cancer, alone or in combination with chemotherapeutic agents.

Countries:
Spain
Regions:
Community of Madrid
Centers:
CNIO, FUNDACION CNIO
Other entities:
Sectors:
Health
Subsectors:
Biotechnology
TRL Level:
TRL 4 – technology validated in lab
BRL Level:
PDF Link:
Download here
Video Link:
Watch it here
Sustainable Development Goal:
Applications

The novel compounds of the invention are not active for PIM1, thus, they are more selective and less toxic than other compounds of the state of art. The compounds of the invention are useful for the treatment of cancer that depends on HASPIN, for example, Burkitt's lymphoma, chronic lymphocytic leukemias, pancreatic cancer, gallbladder carcinoma, bladder cancer, prostate cancer, melanoma, breast cancer, or ovarian cancer. They can be used alone or in combination with chemotherapeutic agents, presenting synergistic combination effects.

Comments

Other related patents

Health

SOL-GEL NANOSTRUCTURED TITANIA RESERVOIRS FOR USE IN THE CONTROLLED RELEASE OF DRUGS IN THE CENTRAL NERVOUS SYSTEM AND METHOD OF SYNTHESIS

Countries
Mexico
Know more
Health

LABORATORY ANIMAL HOUSING SYSTEM FOR THE STUDY OF THE TRANSMISSION OF INFECTIOUS AGENTS THROUGH DIRECT CONTACT (MACHINE-TRANSLATION BY GOOGLE TRANSLATE, NOT LEGALLY BINDING)

Countries
Spain
Know more
Health

EPIGENETIC BIOMARKERS FOR THE DIAGNOSIS AND PREVENTION OF THE OBESITY

Countries
Spain
Know more
Get back to patents directory